Tubulin binding agents and corresponding prodrug constructs

Details Tubulin binding agents and corresponding prodrug constructs Tubulin binding agents and corresponding prodrug constructs

2006-02-21

2006-02-21

Lambkin, Deborah C. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ether doai

C568S633000

Reexamination Certificate

active

07001926

ABSTRACT:
A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, phosphoramidates, and other prodrugs capable of demonstrating selective targeting and destruction of tumor cell vasculature.

REFERENCES:
patent: 3210434 (1965-10-01), Chapman
patent: 3515746 (1970-06-01), Bencze
patent: 3538227 (1970-11-01), Bencze
patent: 3754934 (1973-08-01), Pittet et al.
patent: 3879432 (1975-04-01), Buchholz et al.
patent: 4133814 (1979-01-01), Jones et al.
patent: 4656187 (1987-04-01), Black et al.
patent: 5532382 (1996-07-01), Carlson et al.
patent: 5596106 (1997-01-01), Cullinan et al.
patent: 5886025 (1999-03-01), Pinney
patent: 5952350 (1999-09-01), Cullinan et al.
patent: 5958916 (1999-09-01), Bryant et al.
patent: 6162930 (2000-12-01), Pinney et al.
patent: 6350777 (2002-02-01), Pinney et al.
patent: 6593374 (2003-07-01), Pinney et al.
patent: 6773702 (2004-08-01), Pero et al.
patent: 1028110 (2000-08-01), None
patent: WO 96/40137 (1996-12-01), None
patent: WO 98/39323 (1998-09-01), None
patent: WO 01/68654 (2001-09-01), None
patent: WO 02/060872 (2001-09-01), None
patent: WO 01/77093 (2001-10-01), None
patent: WO 01/79180 (2001-10-01), None
CA 63: 62817, Rutschmann et al, 1965.
CA 129: 189097, 1998.
CA 46: 17739 , Ciba Ltd. 1952.
CA 70:57529 , Bencze, William L. , 1969.
CA 108: 131316 , Kralovec et al. 1988.
Boyd et al., “Some Practical Consideration and Applications of the National Cancer Institute In Vitro Anticancer Drug Discovery Screen”,Drug Development Research. 34:91-109 (1995).
Churcher et al., “Synthesis of the Antitumor Agent Aglycon (±)-Calicheamicinone Using an o-Quinone Monoketal Strategy”,J. Am. Chem. Soc., 120: 13350-10358 (1998).
Clive et al., “Synthesis of (±)-Calicheamicinone by Two Methods”,J. Am. Chem Soc., 120: 10332-10349 (1998).
Cushman et al., “Synthesis of Analogs of 2-Methoxyestradiol with Enhanced Inhibitory Effects on Tubulin Polymerization and Cancer Cell Growth”,J. Med. Chem., 40: 2323-2334 (1997).
Cushman et al., “Synthesis, Antibulin and Antimitotic Activity, and Cytotoxicity of Analogs of 2-Methoyestradiol, an Endogenous Mammalian Metabolite of Estradiol that Inhibits Tubulin Polymerization by Binding to the Colchicine Binding Site”,J. Med. Chem., 38: 2041-2049 (1995).
D'Amato et al., “2-Methoxyestradiol, an Endogenous Mammalian Metabolite, Inhibits Tubulin Polymerization by Interacting at the Colchicines Site”,Proc. Natl. Acad. Sci., 91: 3964-3968 (1994).
Flynn et al., A Novel Palladium-Mediated Coupling Approach to 2,3-Disubstituted.
Benzo[b]thiophenes and Its Application to the Synthesis of Tublin Binding Agents,Organic Letters, 3: 651-654 (2001).
Grese et al., “Structure-Activity Relationships of Selective Estrogen Receptor Modulators: Mofdifications to the 2-Arylbenzothiophene Core of Raloxifene”,J. Med. Chem, 40: 146-167 (1997).
Hamel et al., “Interaction of 2-Methoxyestradiol, an Endogenous Mammalian Metabolite, with Unpolymerized Tubulin and with Tubulin Polymers”,Biochemistry, 35: 1304-1310 (1995).
Jones et al., “Structure-Activity Studies in a Series of 3-Aroyl-2-arylbenzo[b]thiophene Derivatives Leading to [6-Hydroxy-2-(4-hydroxyphenyl)benzo [b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone Hydrochloride (LY156758), a Remarkably Effective Estrogen Antagonist with only Minimal Intrinsic Estrogenicity”:J. Med. Chem., 27: 1057-1066 (1984).
Myers et al., “A Convergent Synthetic Route to (+)-Dynemicin A and Analogs of Wide Structural Variability”J. Am. Chem. Soc., 119: 6072-6094 (1997).
Mullica et al., “characterization and Structural Analyses of Trimethoxy and Triethoxybenzo[b]thiophene”,J. Chem. Cryst., 28: 289-295 (1998).
Palkowitz et al., “Discovery and Synthesis of [6]Hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)benzo[b]thiophene: A Novel, Highly Potent, Selective Estrogen Receptor Modulator”,J. Med. Chem., 40: 1407-1416 (1997).
Pinney et al., “A New Anti-Tubulin Agent Containing the Benzo[b]thiophene Ring System, Bioorganic and Medicinal Chemistry Letter”, 9: 1081-1086 (1999).

Affiliated with

Also associated with

Rating

Tubulin binding agents and corresponding prodrug constructs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tubulin binding agents and corresponding prodrug constructs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tubulin binding agents and corresponding prodrug constructs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3627363